About AMAL Therapeutics
AMAL Therapeutics is a company based in Geneve (Switzerland) founded in 2012 was acquired by Boehringer Ingelheim in July 2019. It operates as a HealthTech. AMAL Therapeutics has raised $36.62 million across 7 funding rounds from investors including AbbVie, Boehringer Ingelheim and Helsinn. AMAL Therapeutics offers products and services including ATP128 and KISIMA®. AMAL Therapeutics operates in a competitive market with competitors including Brii Biosciences, VBI Vaccines, Neon Therapeutics, Affinivax and Osivax, among others.
- Headquarter Geneve, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Amal Therapeutics Sa
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$36.62 M (USD)
in 7 rounds
-
Latest Funding Round
$24.02 M (USD), Series B
Nov 12, 2018
-
Investors
AbbVie
& 11 more
-
Employee Count
Employee Count
-
Acquired by
Boehringer Ingelheim
(Jul 15, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AMAL Therapeutics
AMAL Therapeutics offers a comprehensive portfolio of products and services, including ATP128 and KISIMA®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A vaccine developed for metastatic colorectal cancer treatment.
A platform used for delivering multiple antigens effectively.
Unlock access to complete
Unlock access to complete
Funding Insights of AMAL Therapeutics
AMAL Therapeutics has successfully raised a total of $36.62M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $24.02 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $24.0M
-
First Round
First Round
(01 Jun 2012)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2018 | Amount | Series B - AMAL Therapeutics | Valuation | Boehringer Ingelheim Venture Fund , BioMedPartners | |
| Sep, 2017 | Amount | Series B - AMAL Therapeutics | Valuation | Boehringer Ingelheim Venture Fund , BioMedPartners |
|
| Mar, 2016 | Amount | Series A - AMAL Therapeutics | Valuation | Boehringer Ingelheim Venture Fund |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AMAL Therapeutics
AMAL Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Boehringer Ingelheim and Helsinn. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Founded Year | Domain | Location | |
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in high-tech startups by HTGF.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AMAL Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AMAL Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amal Therapeutics Comparisons
Competitors of AMAL Therapeutics
AMAL Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, VBI Vaccines, Neon Therapeutics, Affinivax and Osivax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
|
| domain | founded_year | HQ Location |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
|
| domain | founded_year | HQ Location |
Tumor-specific neoantigens are identified for personalized cancer vaccine development.
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines against mutating pathogens are developed using nanoparticle technology.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amal Therapeutics
Frequently Asked Questions about AMAL Therapeutics
When was AMAL Therapeutics founded?
AMAL Therapeutics was founded in 2012.
Where is AMAL Therapeutics located?
AMAL Therapeutics is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Who is the current CEO of AMAL Therapeutics?
Laetitia Devy-Dimanche is the current CEO of AMAL Therapeutics.
Is AMAL Therapeutics a funded company?
AMAL Therapeutics is a funded company, having raised a total of $36.62M across 7 funding rounds to date. The company's 1st funding round was a Series A of $3.08M, raised on Jun 01, 2012.
What does AMAL Therapeutics do?
AMAL Therapeutics is engaged in the development of innovative therapeutic vaccines for cancer treatment. The company utilizes its proprietary KISIMA immunisation technology, a self-adjuvanting platform, to deliver multiple antigens in a single vaccine. Its primary focus is on creating effective therapies for cancer, with its lead asset, ATP128, targeting metastatic colorectal cancer. The company operates within the biotechnology sector, aiming to transform prospects for cancer patients through immune system stimulation.
Who are the top competitors of AMAL Therapeutics?
AMAL Therapeutics's top competitors include Brii Biosciences, VBI Vaccines and Osivax.
What products or services does AMAL Therapeutics offer?
AMAL Therapeutics offers ATP128 and KISIMA®.
Who are AMAL Therapeutics's investors?
AMAL Therapeutics has 12 investors. Key investors include AbbVie, Boehringer Ingelheim, Helsinn, Boehringer Ingelheim Venture Fund, and BioMedPartners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.